Mortality Risk Over Time in Patients with Carbapenem-Resistant Gram-Negative Bloodstream Infections: Implications for Recruitment and Timing of Primary Endpoints in Clinical Trials
Publication date: Available online 4 November 2026 Source: International Journal of Antimicrobial Agents Author(s): Abi Manesh, Nagaraj Veerasamy, Pooja Shah, Prasannakumar Palanikumar, Sakshi Parasrampuria, Balaji Veeraraghavan, George M. Varghese, David L. Paterson, A. Sarah Walker
Mortality Risk Over Time in Patients with Carbapenem-Resistant Gram-Negative Bloodstream Infections: Implications for Recruitment and Timing of Primary Endpoints in Clinical Trials. // International Journal of Antimicrobial Agents. – URL: https://www.sciencedirect.com/science/article/pii/S0924857926003481?dgcid=rss_sd_all
Mortality Risk Over Time in Patients with Carbapenem-Resistant Gram-Negative Bloodstream Infections: Implications for Recruitment and Timing of Primary Endpoints in Clinical Trials. International Journal of Antimicrobial Agents. https://www.sciencedirect.com/science/article/pii/S0924857926003481?dgcid=rss_sd_all
“Mortality Risk Over Time in Patients with Carbapenem-Resistant Gram-Negative Bloodstream Infections: Implications for Recruitment and Timing of Primary Endpoints in Clinical Trials.” International Journal of Antimicrobial Agents.
@article{article100411,
title = {Mortality Risk Over Time in Patients with Carbapenem-Resistant Gram-Negative Bloodstream Infections: Implications for Recruitment and Timing of Primary Endpoints in Clinical Trials},
journal = {International Journal of Antimicrobial Agents},
url = {https://www.sciencedirect.com/science/article/pii/S0924857926003481?dgcid=rss_sd_all}
}